Dual-action GLP-1 / GIP for greater metabolic impact.
Get started →A once-weekly dual GLP-1 / GIP medication that acts on two metabolic pathways at once.
Adults seeking greater metabolic impact than a single-pathway GLP-1, under close provider guidance.
By engaging both GLP-1 and GIP receptors it curbs appetite and improves how your body handles glucose and fat. Dosing is stepped up slowly.
Often more pronounced weight and metabolic changes, with the same emphasis on monitoring and sustainable habits.
Complete your intake and a licensed provider will design your protocol.
Get started →This page is illustrative and pre-launch. Tirzepatide is described in general terms; eligibility, dosing, and outcomes are determined by a licensed provider based on your evaluation. Final product and medical copy pending clinical and legal review.